Driver Mutation Part 1: EGFR - 16 Dec 2022
Bevacizumab plus erlotinib versus erlotinib alone in Japenese patients
Furmonertinib versus gefitinib in treatment naive EGFR mutated non small cell lung cancer
7MO Oritinib a third generation EGFR tyrosine kinase inhibitor in locally advanced
Updated Analysis of NEJ009 Gefitinib Alone Versus Gefitinib Plus Chemotherapy
Randomized Trial of first Line Tyrosine Kinase Inhibitor with or without Radiotherapy
Sintilimab In Combination With Anlotinib In Non-Small Cell Lung Cancer Patients With Uncommon EGFR Mutations
Panel Discussion - EGFR mutant NSCLC 1st Line Long Term Outcomes
Simultaneous Tissue and Liquid Next-generation Sequencing after First-line EGFR Tyrosine Kinase Inhibitors Resistance in Advanced NSCLC
Real World Landscape of EGFR C797X Mutation as a Resistance Mechanism
A phase II study of Atezolizumab in combination with bevacizumab
Durvalumab plus chemotherapy in patients with advanced EGFR mutation positive
A Randomised phase II Study of Osimertinib and Bevacizumab Versus Bevacizumab
Capmatinib plus osimertinib versus platinumpermetrexed doublet Chemotherapy
BBT 176 A 4th Generation EGFR TKI for Progressed NSCLC After EGFR TKI Therapy
Panel Discussion - EGFR TKI Resistance
Optimization of treatment options for EGFR mutant Stage III Unresectable NSCLC
Once daily versus twice daily chemoradiation for limited stage small cell
CAPSTONE Trial
Primary analysis from the phase 2 study of continuous talazoparib TALA plus
Comparison of quality of life in patients randomized to high dose once daily QD
SKYCSRAPER 02 Primary results of a phase III randomized double blind
Panel Discussion - Optimal Management ES SCLC Case based Discussion
Development of a rural Comprehensive Cancer Centre
Role of Romiplostim in Chemotherapy induced Thrombocytopenia